-
Mol Cancer (IF=41) The team of Zhou Yanbing from Qingdao University discovered the potential biomarkers of pancreatic cancer for the first time, which is expected to be used in clinical treatment
Time of Update: 2022-08-20
Expression and clinical significance of TIPE3 in PC (picture from Molecular Cancer) Previous studies have shown that RAC1 can be involved in tumor progression, especially the metastasis of PC, and other members of the TIPE family play a role by interacting with RAC1 .
-
WCLC 2022｜NADIM II study: ctDNA levels before treatment are significantly correlated with OS and PFS
Time of Update: 2022-08-20
In the special oral presentation, a new study showed that the level of circulating tumor DNA (ctDNA) before treatment was significantly correlated with overall survival (OS) and progression-free survival (PFS).
-
WCLC Voice of China The best solution for immunotherapy resistance.. The efficacy of immunotherapy after EGFR TKI treatment failure
Time of Update: 2022-08-20
At this year's WCLC conference, a study conducted by Professor Lu Shun's team from the Chest Hospital Affiliated to Shanghai Jiao Tong University explored the best options for patients with oligoprogression after resistance to immunotherapy .
-
How to "build" the most suitable early diagnosis tool for prostate cancer patients in my country?
Time of Update: 2022-08-20
For reference only by medical professionalsAlthough currently available biomarkers and risk calculators require further validation, they have shown initial success in improving the early diagnosis of prostate cancer in Chinese men .
-
2022 Breast Cancer Summer Forum·Northern Salon｜Professor Wang Xiaojia explains the application of CDK4/6 inhibitors in breast cancer patients
Time of Update: 2022-08-20
"2022 Breast Cancer Summer Forum·Northern Salon" will be held in Beijing on July 30, 2022 . The conference invites experts and scholars to share the latest progress in breast cancer surgery and medica
-
5 times of metastasis, 4 times of surgery, the OS of colorectal cancer exceeds 8 years!
Time of Update: 2022-08-20
The patient developed colorectal cancer lung metastases, thyroid metastases, left and right adrenal metastases, and multiple lung metastases successively .
The patient developed colorectal cancer lung metastases, thyroid metastases, left and right adrenal metastases, and multiple lung metastases successively .
-
Exploration of veneclax combined with geeritinib in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Time of Update: 2022-08-20
Among FLT3 mut patients previously exposed to veneclax (n=10), the mCRc rate was 60% and the median OS was 6.
Among FLT3 mut patients previously exposed to veneclax (n=10), the mCRc rate was 60% and the median OS was 6.
-
New treatment options for unresectable hepatocellular carcinoma
Time of Update: 2022-08-20
CommentA single dose of tremelimumab combined with subsequent durvalumab provides a new treatment option for patients with advanced hepatocellular carcinoma with a 3-year overall survival rate of 30% .
-
Standardized monitoring and testing to help precise treatment, the series of lectures on standardized diagnosis, treatment and management of chronic myeloid leukemia has set sail again
Time of Update: 2022-08-20
On July 6 and 30, 2022, "Chronic Myeloid Leukemia (CML) Standardized Diagnosis and Management Series Tour Lectures" were held in the "Cloud" successively . "CML Standardized Diagnosis and Treatment To
-
【WCLC】Broken cocoon and turned into a butterfly and reborn | Amivantamab combined with Lazertinib in the first-line treatment of patients with EGFR-sensitive mutation PFS may exceed 28 months!
Time of Update: 2022-08-20
At present, the researchers are conducting a large-scale phase III study MARIPOSA to compare the efficacy and safety of the Amivantamab + Lazertinib regimen and the first-line treatment of osimertinib in patients with EGFR-sensitive mutated NSCLC, which is worth looking forward to .
-
2022 Palliative Conference - Cancer-Related Fatigue Symposium Demonstrates Unique Advantages
Time of Update: 2022-08-20
In addition to the treatment methods of Western medicine, researches at home and abroad in recent years have shown that traditional Chinese medicine has achieved some positive effects in improving the symptoms and quality of life of cancer patients with CRF .
-
The first issue of divine journal CA (IF=286) officially published global cancer statistics: nearly 10 million cancer patients died worldwide, and breast cancer became the number one cancer in the world
Time of Update: 2022-08-20
Lung cancer is the most common cancer with the highest mortality rate in men, followed by prostate cancer and colorectal cancer, followed by liver cancer and colorectal cancer; in women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths.
-
Effects of radiotherapy on subjective cognitive function in patients with glioma
Time of Update: 2022-08-20
A prospective study evaluating the hippocampal structure of patients with WHO grade III or IV gliomas receiving standard high-dose radiation therapy Changes and subjective memory dysfunction and its predictors, results published online June 2022 in Radiotherapy and Oncology .
-
Science sub-journal: Scientists reveal for the first time the mechanistic link between circadian clock disturbance and colorectal cancer
Time of Update: 2022-08-20
Taken together, these data suggest that disruption of the circadian clock drives APC LOH over-activation of Wnt signaling and enhances myc-dependent glycolytic metabolism to accelerate colorectal cancer progression .
-
AJRCCM (IF=31) The evidence is here!
Time of Update: 2022-08-20
On August 9, 2022, Zhong Rong's team from Huazhong University of Science and Technology published online in the American Journal of Respiratory and Critical Care Medicine (IF=31) titled "In Utero and Childhood/Adolescence Exposure to Tobacco Smoke, Genetic Risk and Lung Cancer Incidence and Mortality in Adulthood", which included a total of 432,831 participants from the UK Biobank study .
-
Express Screens Suitable Lung Cancer Patients for Blockbuster ADC Therapy, Liquid Biopsy Approved by FDA
Time of Update: 2022-08-20
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content TeamImage source: Guardant Health official websiteWuXi AppTec provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, covering chemical drug R&D and production, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and production and other fields .
-
Efficacy and safety of ripretinib and sunitinib in the treatment of advanced gastrointestinal stromal tumors
Time of Update: 2022-08-20
(If you need the original text of the literature, you can add Xiaobian WeChat yxj_oncology to get it)1Comparison of efficacy and safety of ripretinib and sunitinib in the treatment of advanced gastrointestinal stromal tumors▎Clinical problems:Both sunitinib and ripatinib are approved for patients with advanced gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib .
-
Salvage chemotherapy after failure of PD-1 inhibitor therapy is effective in improving outcomes in patients with R/R cHL
Time of Update: 2022-08-20
Research result1 Patient characteristicsFrom March 2017 to November 2020, 28 patients with cHL who were refractory to PD-1 inhibitors (n=10, 36%) or had disease progression after initial response (n=18, 64) were enrolled in the study %), the median age at diagnosis was 29 years (range: 19-71), and the baseline characteristics are detailed in Table 1 .
-
ALK+NSCLC: Just one step away from "live longer" to "have to live better"
Time of Update: 2022-08-20
*For medical professional reading reference onlyBrigatinib officially entered clinical application in China, helping clinical patients to fully benefit Tumor-targeted therapy has changed the clinical practice of lung cancer, making anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) move toward "precision" and "long survival" .
-
J Clin Oncol: Rituximab + Lenalidomide + Ibrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Time of Update: 2022-08-19
This is an investigator-initiated, single-arm, Phase 2 clinical trial that enrolled 60 patients with newly diagnosed non-germinal center B-cell-like DLBCL to receive rituximab (375 mg/m2, day 1) , lenalidomide (25 mg/day, days 1-10) and ibrutinib (560 mg/day) (RLI) were treated sequentially, with 21 days as a course of treatment .
